Clinical Trial SuccessLete-cel demonstrated an overall response rate of 42% for sarcoma patients, significantly higher than current therapies achieving only 4-7%.
Insurance And Market AdoptionInsurance plans representing over 67% of commercial lives have formally covered Tecelra, indicating strong market acceptance.
Strategic ExpansionADAP now expects to launch approximately 30 centers by the end of the year, which will cover around 80% of patients treated in sarcoma centers of excellence.